1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends
  4. > Biomarkers in Alzheimers Disease

Biomarkers in Alzheimers Disease

  • July 2014
  • -
  • Insight Pharma Reports
  • -
  • 95 pages

Overview
Biomarkers in Alzheimer’s Disease is focused on the biomarker identification and development in patients with Alzheimer’s Disease. As a spin-off of Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders, this report focuses on the Alzheimer’s Disease space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing the use of biomarkers for Alzheimer’s Disease, Biomarkers in Alzheimer’s Disease captures market growth of biomarkers, advantages, disadvantages, and validation techniques.

Experts interviewed in this report include:
Dr. Jens Wendland, Head of Neuroscience Genetics, Precision Medicine, PharmaTherapeutics, Pfizer Worldwide R&D
Dr. Howard J. Federoff, Executive Vice President for Health Sciences, Georgetown University
Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers
Also available in this report is extensive survey data exclusively conducted for this report. Illustrated by 30 figures captured in an in-depth analysis, this section features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications.
To add even more to the robustness of this report, Insight Pharma Reports also garnered a table of clinical trial information and pipeline data related to Alzheimer’s Disease. This table features companies, targets, clinical phases, and brief target/product descriptions.

Table Of Contents

Biomarkers in Alzheimers Disease
Table of Contents
Executive Summary

CHAPTER 1: The Focus of this Report

CHAPTER 2: Biomarkers and Their Clinical Utility
What are Biomarkers?
Advantages of Biomarkers
Clinical Endpoints vs. Surrogate Endpoints
Advantages of Biomarkers as Surrogate Endpoints
Disadvantages to Biomarkers as Surrogate Endpoints
How are Biomarkers Validated?

CHAPTER 3: Biomarkers in Neurodegenerative Disorders

CHAPTER 4: Mild Cognitive Impairment and Alzheimer's Disease
How is it Related to Alzheimer's Disease?
Conflicting Evidence: Mild Cognitive Impairment or Alzheimer's Disease?
Biomarkers and Candidates for Alzheimer's Disease
Cerebrospinal fluid Analysis vs. Plasma Analysis
Current Biomarkers
Phospholipid Biomarkers
Single Nucleotide Polymorphisms and Apolipoprotein E
Testosterone and Hormone Levels
Interview with Dr. Howard Federoff
Interview with Dr. Jens Wendland

CHAPTER 5: Biomarkers for Diagnostics
Atlantic Biomarkers: Research Background
Mass-Spectrometry Assays for Biomarkers
Impact on Healthcare
Interview with Dr. Andreas Jeromin
Company Background
Neurobiomarker Research
Mass Spectrometry-Based Assays

CHAPTER 6: Survey Results

CHAPTER 7: Clinical Trials and Pipeline Information

References

About Cambridge Healthtech Institute

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Biobanking: Technologies and Global Markets

Biobanking: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

Use this report to: - Analyze the role biobanks play in the development of new drugs for specific disease treatments. - Learn about the prevailing market size for certain biobank services available ...

Non-alcoholic Steatohepatitis Biomarkers Market and Pharmaceutical Industry, Academic Research Institute, Hospitals, and Diagnostic Laboratories - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Non-alcoholic Steatohepatitis Biomarkers Market and Pharmaceutical Industry, Academic Research Institute, Hospitals, and Diagnostic Laboratories - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Non-alcoholic Steatohepatitis Biomarker Market: Overview Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). ...

Biomarkers Market by Product, Type, Disease Indication, Application - Global Forecast to 2021

Biomarkers Market by Product, Type, Disease Indication, Application - Global Forecast to 2021

  • $ 5650
  • Industry report
  • February 2017
  • by MarketsandMarkets

The global biomarkers market is estimated to reach USD 53.34 billion by 2021 from USD 27.95 billion in 2016, at a CAGR of 13.8% from 2016 to 2021. Increasing diagnostic applications of biomarkers, increasing ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics

  • February 2017
    6 pages
  • Cancer  

  • United Kingdom  

    United States  

View report >

Genomics Statistics in Spain

  • February 2017
    5 pages
  • Genomics  

    Advanced Materi...  

  • Spain  

View report >

Oleochemicals Industry

  • January 2017
    8 pages
  • Oleochemicals  

    Milk  

    Genetic  

View report >

Related Market Segments :

Biomarker

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.